Home › Search
Search
314 results for "lecanemab".
Research summaries 285
Showing the best 200 of 285, 81–90, page 9 of 20. Filter these by subject, year and score in the research library →
-
Research summaries · alzhub.org/study/population-pharmacokinetics-and-exposure-response-analyses-of-safety-39207112
Lecanemab (Leqembi®) was recently approved by health authorities in the United States, Japan, and China to treat early Alzheimer's disease (AD), including patients with mild cognitive impairment (MCI) or mild dementia due to …
-
Real-world lecanemab adoption in Japan 1 year after launch: Insights from 311 specialists on infrastructure and reimbursement barriersResearch summary
Research summaries · alzhub.org/study/real-world-lecanemab-adoption-in-japan-1-year-after-launch-insights-41114448
Lecanemab was approved for early Alzheimer's disease in Japan, with ≈ 6000 patients treated in the first year post approval. This study explores real-world practices, challenges, and potential solutions. We conducted an …
-
Research summaries · alzhub.org/study/safety-and-effectiveness-of-the-anti-amyloid-monoclonal-antibody-mab-40051090
… antibodies, such as lecanemab, provides a promising novel treatment pathway with potential disease-modifying effects for patients with early Alzheimer's disease (AD). Lecanemab, which gained marketing approval by the United …
-
Safety and efficacy of lecanemab for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trialsResearch summary
Research summaries · alzhub.org/study/safety-and-efficacy-of-lecanemab-for-alzheimer-s-disease-a-systematic-37213538
… effectiveness and safety of lecanemab on subjects with Alzheimer's disease (AD). Methods We screened the literature published before February 2023 in PubMed, Embase, Web of Science, and Cochrane that were searched for randomized …
-
Safety of switching from lecanemab to donanemab in 20 consecutive patients with Alzheimer's diseaseResearch summary
Research summaries · alzhub.org/study/safety-of-switching-from-lecanemab-to-donanemab-in-20-consecutive-40708311
… disease who switched from lecanemab to donanemab. No new amyloid-related imaging abnormalities (ARIA) or significant adverse events were observed during the first five donanemab infusions. Prior exposure to lecanemab may reduce …
-
Research summaries · alzhub.org/study/a-randomized-double-blind-phase-2b-proof-of-concept-clinical-trial-in-33865446
Background Lecanemab (BAN2401), an IgG1 monoclonal antibody, preferentially targets soluble aggregated amyloid beta (Aβ), with activity across oligomers, protofibrils, and insoluble fibrils. BAN2401-G000-201, a randomized …
-
Amyloid and Tau Cerebrospinal Fluid Biomarker Normalization in a Patient with Alzheimer’s Disease treated with Lecanemab: A Case ReportResearch summary
Research summaries · alzhub.org/study/amyloid-and-tau-cerebrospinal-fluid-biomarker-normalization-in-a-1d9e787e
… biomarkers following lecanemab therapy in a patient with Alzheimer’s disease (AD). Methods A woman (APOEε3/ε4) was diagnosed with AD after clinical, neurocognitive, and CSF evaluation. She received 10mg/kg of intravenous …
-
Amyloid solutions: lecanemab, gantenerumab, and donanemab in the treatment of Alzheimer's diseaseResearch summary
Research summaries · alzhub.org/study/amyloid-solutions-lecanemab-gantenerumab-and-donanemab-in-the-2abd646d
… disease trajectory. Lecanemab’s selective affinity for protofibrillar Aβ disrupts early neurotoxic aggregates, providing a proactive approach for mitigating synaptic dysfunction. Donanemab, by targeting pyroglutamate-modified …
-
Lecanemab for Patients With Early Alzheimer Disease: Bayesian Analysis of a Phase 2b Dose-Finding Randomized Clinical TrialResearch summary
Research summaries · alzhub.org/study/lecanemab-for-patients-with-early-alzheimer-disease-bayesian-analysis-37040116
… 587 were assigned to a lecanemab 201 treatment group (median age, 72 years [range, 50-90 years]; 272 female [46%]). The bayesian approach improved the efficiency of a clinical trial by prospectively adapting to the trial's …
-
Research summaries · alzhub.org/study/lecanemab-in-symptomatic-psen1-p-met233val-early-onset-alzheimer-s-42676462
… (ADAD) variant for which lecanemab response data are unavailable. Methods A 34-year-old symptomatic PSEN1 p .Met233Val carrier (APOE ε3/ε3) was prospectively followed through 26 lecanemab infusions over 12 months, with serial …
How this search works
There is no outside search company involved. The site builds its own index by reading its own pages — the same words you would see on the page — and each result shows a literal snippet of that text with your words highlighted. Nothing is summarised or rewritten by a machine in between.
One addition, made by hand: a short list of everyday words that our pages cover under another name. Search "symptoms" and you are also shown The 10 warning signs; "medication" leads to Treatments & medicines; "hotline" to the helplines. A result reached that way shows the page's own description, and it only ever points to a page that already covers the subject.
28381 pages, questions, glossary terms and research summaries are indexed, last rebuilt 2026-11-05. Las páginas en español también aparecen en estos resultados. The clinical trial records are not in this index — they have their own finder, which searches all trial titles, sponsors and drugs directly.